The shares of an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products hit a 10 percent upper circuit from the previous closing price. The company’s financial results show robust Revenue growth of 17 percent Y-O-Y, and the Net profits are up by 61 percent The company also sets a target of 500 crore revenue by 2028
The shares of Sat Kartar Shopping Ltd, with a market capitalization of Rs. 282.94 crores on Monday. Its shares are trading at a CMP of Rs 179.70, against the previous closing price of Rs 170.80. The stock has hit a 10 percent upper circuit high, reaching a high of Rs 187.85 Intraday
What Happened
Sat Kartar Shopping Limited, an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products, announced its results for the Financial year ‘25. Its Revenue grew by 17 percent YoY from Rs 74.8 Crores in H2FY24 to Rs 87.1 Crores in H2FY25, and it has increased by close to 15 percent half-yearly from Rs 75.8 Crores in H1FY25 to Rs 87.1 Crores in H2FY25.
Its Net Profit grew by 61 percent YoY from Rs. 3.72 Crores in H2FY24 to Rs. 5.99 Crores in H2FY25. The Net profits have grown by 56.80 percent half-yearly from Rs. 3.82 Crores in H1FY25 to Rs. 5.99 Crores in H2FY25.
The company’s Earnings Before Interest, Depreciation, and Taxes (EBIDT) has also grown by 48 percent YOY from Rs 5.83 crores in H2FY24 to Rs 8.60 crores in H2FY25. Its EPS has also grown by 15 percent half-yearly, from Rs. 3.30 in H1FY25 to Rs. 3.80 in H2FY25. The company has recommended the final dividend of Rs. 0.70 per equity share for the financial year 2024-2025
Sat Kartar Shopping Ltd has also announced the acquisition of a 76 percent equity stake in Plantomed Neutraceuticals Private Limited, an Ayurveda healthcare company focused on natural wellness solutions and therapeutic lifestyle products. The strategic acquisition, valued at approximately Rs 90 lakhs and expected to close by June 2025, aims to enhance brand consolidation, product expansion, and operational alignment with Sat Kartar’s long-term vision.
Future Prospect
Sat Kartar Shopping Ltd outlines a strategic growth roadmap focused on personalized customer engagement, increased marketing investment, and service enhancement through specialized medical consultants. The company plans to expand into complementary wellness verticals to tap into high-margin segments and aims for 40–50 percent growth over the next three years. Additionally, it is committed to expanding its footprint across India, bringing Ayurveda to even the most underserved and remote regions.
Sat Kartar Shopping Ltd aims to scale its revenue from Rs 163 crores in FY25 to Rs 500 crores by FY28, while improving PAT margins from 6 percent to 12 percent. This growth will be driven by a combination of organic expansion, strategic acquisitions, entry into new geographies, and the launch of innovative product lines. The company’s vision reflects a strong focus on both financial performance and market diversification.
About the company
Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners. Dedicated to promoting a healthier way of life, the company is rapidly expanding its footprint across India, including underserved and remote regions.
Written by Likesh babu S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
